Arterial disease in lupus and secondary antiphospholipid syndrome: Association with anti-beta2-glycoprotein I antibodies but not with antibodies against oxidized low-density lipoprotein

British Journal of Rheumatology

Volumn 37, Issue 8, 1998, Pages 883-888

  Romero, F I ^a   Amengual, O ^a   Atsumi, T ^a   Khamashta, M A ^a   Tinahones, F J ^b   Hughes, G R V ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Anticardiolipin antibody; Antiphospholipid antibody; Atherosclerosis; Haemolytic anaemia; Thrombosis

Indexed keywords

AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; IMMUNOGLOBULIN G ANTIBODY; LOW DENSITY LIPOPROTEIN;

ADOLESCENT; ADULT; AGED; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; ARTERY DISEASE; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOLYTIC ANEMIA; HUMAN; LUPUS ERYTHEMATOSUS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHOOL CHILD; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

EID: 0031856327     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/37.8.883     Document Type: Article

References (43)

1. Kitagawa Y, Gotoh F, Koto A, Okayasu H. Stroke in systemic lupus erythematosus. Stroke 1990;21:1533-9.
2. Haider YS, Roberts WC. Coronary arterial disease in systemic lupus erythematosus. Quantification of degree of narrowing in 22 necropsy patients (21) women aged 16 to 37 years. Am J Med 1981;70:775-81.
3. Tsakraklides VG, Blieden IC, Edwards JE. Coronary atherosclerosis and myocardial infarction associated with systemic lupus erythematosus. Am Heart J 1974;87: 637-41.
4. Jonsson H, Nived O, Sturfelt G. Outcome in systemic lupus erythematosus: A prospective study of patients from a defined population. Medicine 1989;68:141-50.
5. Bulkley BH, Roberts WC. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. Am J Med 1975;58:243-64.
6. Roubey RAS. Autoantibodies to phospholipid-binding proteins: A new view of lupus anticoagulants and other 'antiphospholipid' antibodies. Blood 1994;84:2854-67.
7. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990;336: 177-8.
8. Galli M, Comfurius P, Maasen C et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;336:952-3.
9. 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990;87:4120-4.
10. 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994;179: 457-62.
11. 2-glycoprotein I in the absence of phospholipid: Importance of antigen density and bivalent binding. J Immunol 1995;154:954-60.
12. 2 glycoprotein I-induced antiphospholipid antibodies. J Lab Clin Med 1995;125:775-8.
13. Yla-Herttuala S, Palinsky W, Rosenfeld ME et al. Evidence for the presence of oxidatively modified low-density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989;84:1086-95.
14. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994;344:793-5.
15. Berliner JA, Navab M, Fogelman AM et al. Oxidation, inflammation and genetics. Circulation 1995;91: 2488-96.
16. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991;88: 1785-92.
17. Penn MS, Chisolm GM. Oxidized lipoproteins, altered cell function and atherosclerosis. Atherosclerosis 1994; 108(suppl.):S21-9.
18. Steinberg D. Role of oxidized LDL and antioxidants in atherosclerosis. Adv Exp Med Biol 1995;369:39-48.
19. 2-glycoprotein I and cardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997;107:569-73.
20. Vaarala O. Antiphospholipid antibodies and atherosclerosis. Lupus 1996;5:442-7.
21. Wu R, Lefvert AK. Autoantibodies against oxidized low density lipoproteins (ox-LDL): Characterisation of antibody isotype, subclass, affinity and effect on the macrophage uptake of ox-LDL. Clin Exp Immunol 1995;102:174-80.
22. Parums DV, Brown DL, Mitchinson MJ. Serum antibodies to oxidized low density lipoprotein and ceroid in chronic periaortitis. Arch Pathol Lab Med 1990;114:383-7.
23. Salonen JK, Yla-Herttuala S, Yamamoto L et al. Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet 1992;339:883-7.
24. Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T. Crossreaction between antibodies to oxidized low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993;341:923-5.
25. 2-glycoprotein I on the reactivity of antioxidized low-density lipoprotein antibody to oxidized low-density lipoprotein. Am J Hematol 1996;52:114-6.
26. 2-glycoprotein I antibodies: Detection and association with thrombosis. Br J Haematol 1995;89:397-402.
27. Balestrieri G, Tincani A, Spatola L et al. Anti beta 2-glycoprotein I antibodies: A marker of antiphospholipid syndrome? Lupus 1995;4:122-30.
28. Teixido M, Font J, Reverter JC et al. Anti beta 2-glycoprotein I antibodies: A useful marker for the antiphospholipid syndrome. Br J Rheumatol 1997;36: 113-6.
29. 2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum 1996;39:1466-74.
30. 2-glycoprotein I binding antibodies are associated with a history of thromboembolic complications in patients with SLE and primary antiphospholipid syndrome. Br J Rheumatol 1995;34:1031-6.
31. 2-glycoprotein I than with antiphospholipid antibodies. J Rheumatol 1995;22: 1899-906.
32. 2-glycoprotein I in patients with antiphospholipid syndrome. Br J Rheumatol 1996;35:1239-43.
33. Amengual O, Atsumi T, Khamashta MA, Tinahones FJ, Hughes GRV. Autoantibodies against oxidized low-density lipoprotein in antiphospholipid syndrome. Br J Rheumatol 1997;36:964-8.
34. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
35. Harris EN. Antiphospholipid antibodies. Br J Haematol 1990;74:1-9.
36. Palinsky W, Yla-Herttuala S, Rosenfeld ME et al. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 1990;10:325-35.
37. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039-57.
38. Cervera R, Khamashta MA, Font J et al. Systemic lupus erythematosus: Clinical and immunological patterns of disease expression in a cohort of 1000 patients. Medicine 1993;72:113-24.
39. Alarcon-Segovia D, Deleze M, Oria CV et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine 1989; 68:353-65.
40. Cabral AR, Cabiedes J, Alarcon-Segovia D. Haemolytic anaemia related to an IgM autoantibody to phosphatidylcholine that binds in vitro to stored and to bromelain-treated erythrocytes. J Autoimmun 1990;3:773-87.
41. Del Papa N, Meroni PL, Barcellini W et al. Antiphospholipid antibodies cross-reacting with erythrocyte membranes. A case report. Clin Exp Rheumatol 1992;10:395-9.
42. Lopez-Soto A, Cervera R, Font J et al. Isotype distribution and clinical significance of antibodies to cardiolipin, phosphatidic acid, phosphatidylinositol and phosphatidylserine in systemic lupus erythematosus: Prospective analysis of 92 patients. Clin Exp Rheumatol 1997; 15: 143-9.
43. Arvieux J, Roussel B, Schweizer B, Colomb MG. Erythrocyte binding of antiphospholipid antibodies. Clin Exp Rheumatol 1993;11:352-3.